702 related articles for article (PubMed ID: 26658106)
21. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
22. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer.
Shimizu K; Nakata M; Hirami Y; Yukawa T; Maeda A; Tanemoto K
J Thorac Oncol; 2010 May; 5(5):585-90. PubMed ID: 20234320
[TBL] [Abstract][Full Text] [Related]
23. CD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer.
Paulsen EE; Kilvaer T; Khanehkenari MR; Maurseth RJ; Al-Saad S; Hald SM; Al-Shibli K; Andersen S; Richardsen E; Busund LT; Bremnes R; Donnem T
Neoplasia; 2015 Nov; 17(11):839-48. PubMed ID: 26678911
[TBL] [Abstract][Full Text] [Related]
24. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma.
Ryschich E; Nötzel T; Hinz U; Autschbach F; Ferguson J; Simon I; Weitz J; Fröhlich B; Klar E; Büchler MW; Schmidt J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):498-504. PubMed ID: 15701833
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer.
Kinoshita T; Muramatsu R; Fujita T; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Kudo-Saito C; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H; Kawakami Y
Ann Oncol; 2016 Nov; 27(11):2117-2123. PubMed ID: 27502728
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Karpathiou G; Casteillo F; Giroult JB; Forest F; Fournel P; Monaya A; Froudarakis M; Dumollard JM; Prades JM; Peoc'h M
Oncotarget; 2017 Mar; 8(12):19310-19322. PubMed ID: 28038471
[TBL] [Abstract][Full Text] [Related]
27. Stromal CD4/CD25 positive T-cells are a strong and independent prognostic factor in non-small cell lung cancer patients, especially with adenocarcinomas.
Kayser G; Schulte-Uentrop L; Sienel W; Werner M; Fisch P; Passlick B; Zur Hausen A; Stremmel C
Lung Cancer; 2012 Jun; 76(3):445-51. PubMed ID: 22300751
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
[TBL] [Abstract][Full Text] [Related]
29. The Prognostic Value of Sex-Determining Region Y-Box 2 and CD8+ Tumor-Infiltrating Lymphocytes in Limited-Stage Small-Cell Lung Cancer.
Lee J; Jung YY; Lee JH; Hong M; Hwang HW; Hong SA; Hong SH
Oncology; 2021; 99(8):528-538. PubMed ID: 34107469
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of tumor-infiltrating CD8⁺ or CD3⁺ T lymphocytes and interleukin-2 expression in radically resected non-small cell lung cancer.
Tian C; Lu S; Fan Q; Zhang W; Jiao S; Zhao X; Wu Z; Sun L; Wang L
Chin Med J (Engl); 2015 Jan; 128(1):105-10. PubMed ID: 25563322
[TBL] [Abstract][Full Text] [Related]
31. CD8+ T cells expressing IL-10 are associated with a favourable prognosis in lung cancer.
Miotto D; Lo Cascio N; Stendardo M; Querzoli P; Pedriali M; De Rosa E; Fabbri LM; Mapp CE; Boschetto P
Lung Cancer; 2010 Sep; 69(3):355-60. PubMed ID: 20089329
[TBL] [Abstract][Full Text] [Related]
32. Infiltrating immune cells, but not tumour cells, express FasL in non-small cell lung cancer: No association with prognosis identified in 3-year follow-up.
Toomey D; Smyth G; Condron C; Kelly J; Byrne AM; Kay E; Conroy RM; Broe P; Bouchier-Hayes D
Int J Cancer; 2003 Jan; 103(3):408-12. PubMed ID: 12471625
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
34. Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Yoneda K; Kuwata T; Kanayama M; Mori M; Kawanami T; Yatera K; Ohguri T; Hisaoka M; Nakayama T; Tanaka F
Br J Cancer; 2019 Sep; 121(6):490-496. PubMed ID: 31388183
[TBL] [Abstract][Full Text] [Related]
35. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma.
Wald O; Izhar U; Amir G; Avniel S; Bar-Shavit Y; Wald H; Weiss ID; Galun E; Peled A
J Immunol; 2006 Nov; 177(10):6983-90. PubMed ID: 17082613
[TBL] [Abstract][Full Text] [Related]
36. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity of CD8
Obeid JM; Wages NA; Hu Y; Deacon DH; Slingluff CL
Cancer Immunol Immunother; 2017 Jan; 66(1):33-43. PubMed ID: 27770170
[TBL] [Abstract][Full Text] [Related]
38. High p-Smad2 expression in stromal fibroblasts predicts poor survival in patients with clinical stage I to IIIA non-small cell lung cancer.
Chen Y; Xing P; Chen Y; Zou L; Zhang Y; Li F; Lu X
World J Surg Oncol; 2014 Nov; 12():328. PubMed ID: 25373709
[TBL] [Abstract][Full Text] [Related]
39. Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Uruga H; Bozkurtlar E; Huynh TG; Muzikansky A; Goto Y; Gomez-Caraballo M; Hata AN; Gainor JF; Mark EJ; Engelman JA; Lanuti MD; Mino-Kenudson M
J Thorac Oncol; 2017 Mar; 12(3):458-466. PubMed ID: 27815126
[TBL] [Abstract][Full Text] [Related]
40. Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.
Donnem T; Al-Shibli K; Al-Saad S; Busund LT; Bremnes RM
J Thorac Oncol; 2009 May; 4(5):578-85. PubMed ID: 19318994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]